Related Experiment Videos
Controlling lipid levels in diabetes
1University of Helsinki, Department of Medicine, Finland.
Insights
Patients with type 2 diabetes have higher risks of coronary heart disease (CHD). Statins effectively lower LDL cholesterol and triglycerides, reducing CHD events in diabetic patients with dyslipidaemia.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes significantly increases coronary heart disease (CHD) risk.
- Diabetic dyslipidaemia, characterized by high triglycerides, low HDL, and small, dense LDL, is a key CHD risk factor.
- Standard diabetes management often fails to fully correct these lipid abnormalities.
Purpose of the Study:
- To review the role of statins in managing diabetic dyslipidaemia.
- To highlight the efficacy of statins in reducing CHD events in diabetic patients.
Main Methods:
- Review of current treatment guidelines and recent clinical trial evidence.
- Focus on statin therapy for lipid management in type 2 diabetes.
Main Results:
- Statins are effective and well-tolerated for lowering LDL cholesterol without negatively impacting glycaemic control.
- Emerging evidence supports statins for treating elevated triglycerides.
- Lipid-lowering therapy with statins significantly reduces CHD events in patients with diabetic dyslipidaemia.
Conclusions:
- Statins are a crucial therapeutic intervention for diabetic dyslipidaemia.
- Statin therapy offers significant cardiovascular protection for patients with type 2 diabetes and dyslipidaemia.
Abstract:
Coronary heart disease (CHD) is associated with a 2- to 4-times greater risk of morbidity and mortality in patients with type 2 diabetes than in non-diabetic individuals. Dyslipidaemia is an important CHD risk factor in diabetic patients. The key atherogenic features of diabetic dyslipidaemia are elevated levels of serum triglycerides, low levels of high density lipoprotein (HDL) cholesterol, and the preponderance of small, dense low density lipoprotein (LDL). As a result, treatment guidelines for diabetic dyslipidaemia recommend elevated LDL cholesterol and triglyceride levels and low HDL cholesterol levels as targets of therapy. Unfortunately, however, these lipid abnormalities often persist despite best efforts to control hyperglycaemia, improve diet, and increase physical exercise, and therefore demand specific therapeutic intervention. Statins are the first choice for LDL cholesterol lowering as they are effective and well tolerated, and do not have adverse effects on glycaemic control. Furthermore, recent evidence suggests that statins may also be employed to treat moderately elevated levels of triglycerides. An increasing number of primary and secondary prevention trials have shown that lipid-lowering therapy with statins can significantly reduce the risk of CHD events in patients with diabetic dyslipidaemia.